Market Cap
Low in industry
PE TTM
Negative PE TTM
PEG TTM
Price to Book
Negative Price to Book
Beta 1Year
Very Low volatility
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Simba Gill | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 1,171 | 16,408 | - | - | Restricted Stock Units | |
| Simba Gill | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 1,171 | 4,096 (0%) | 0% | - | Common Stock | |
| Simba Gill | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 342 | 3,754 (0%) | 0% | 9.5 | 3,252 | Common Stock |
| Marella Thorell | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 2,004 | 9,069 (0%) | 0% | 9.5 | 19,058 | Common Stock |
| Marella Thorell | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 13,000 | - | - | Restricted Stock Units | |
| Marella Thorell | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 11,073 (0%) | 0% | - | Common Stock | |
| Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 13,000 | - | - | Restricted Stock Units | |
| Duncan McHale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 3,434 | 7,941 (0%) | 0% | 9.5 | 32,657 | Common Stock |
| Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 11,375 (0%) | 0% | - | Common Stock | |
| Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,625 | 13,250 | - | - | Restricted Stock Units | |
| Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,625 | 19,752 (0%) | 0% | - | Common Stock | |
| Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 3,128 | 16,624 (0%) | 0% | 9.5 | 29,747 | Common Stock |
| Jeffrey R. Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 2,000 | - | - | Stock Option (Right to Buy) | |
| Alexander C. Reynolds | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 2,000 | - | - | Stock Option (Right to Buy) | |
| Melas Theo Kyriazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) | |
| Julie H. McHugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Robert L. Rosiello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Jose-Carlos Gutierrez-Ramos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| John A. Hohneker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Iain B. McInnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Tonya Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 0.14 per share. | 23 May 2023 | 22,571 | 262,557 (0%) | 0% | 0.1 | 3,201 | Common Stock |
| Simba Gill | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 3,537 | 58,512 (0%) | 0% | 0.1 | 444 | Common Stock |
| Marella Thorell | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 38,531 | 91,469 (0%) | 0% | 0.1 | 4,836 | Common Stock |
| Duncan McHale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 66,730 | 97,516 (0%) | 0% | 0.1 | 8,375 | Common Stock |
| Mark Bodmer | CSO, President of R&D | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 68,014 | 285,128 (0%) | 0% | 0.1 | 8,536 | Common Stock |
| Simba Gill | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 23,437 | 351,563 | - | - | Restricted Stock Units | |
| Marella Thorell | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 390,000 | - | - | Restricted Stock Units | |
| Marella Thorell | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 130,000 (0%) | 0% | - | Common Stock | |
| Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 390,000 | - | - | Restricted Stock Units | |
| Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 164,246 (0%) | 0% | - | Common Stock | |
| Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 132,500 | 353,142 (1%) | 0% | - | Common Stock | |
| Mark Bodmer | CSO, President of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 132,500 | 397,500 | - | - | Restricted Stock Units | |
| Robert L. Rosiello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 375,000 | 375,000 | - | - | Restricted Stock Units | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 1,125,000 | 1,125,000 | - | - | Stock Option (Right to Buy) | |
| Marella Thorell | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 520,000 | 520,000 | - | - | Restricted Stock Units | |
| Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 520,000 | 520,000 | - | - | Restricted Stock Units | |
| Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 530,000 | 530,000 | - | - | Restricted Stock Units | |
| Mark D. Plinio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.88 per share. | 31 Jan 2023 | 1,250 | 3,750 (0%) | 0% | 0.9 | 1,100 | Common Stock |
| Stephen J. Carriere | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.06 per share. | 19 Jan 2023 | 151 | 203 (0%) | 0% | 1.1 | 160 | Common Stock |
| Stephen J. Carriere | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2023 | 354 | 1,063 | - | - | Restricted Stock Units | |
| Stephen J. Carriere | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2023 | 354 | 354 (0%) | 0% | - | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,874 | 0 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,053 | 0 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,874 | 93,932 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,053 | 91,058 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Melas Theo Kyriazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Julie H. McHugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| John A. Hohneker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Iain B. McInnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,873 | 89,005 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,873 | 2,874 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,052 | 2,053 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,052 | 86,132 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 27 May 2022 | 17,123 | 84,080 (0%) | 0% | 1.5 | 25,000 | Common Stock |
| Duncan McHale | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 27 May 2022 | 34,246 | 34,246 (0%) | 0% | 1.5 | 49,999 | Common Stock |
| Ara Darzi | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 27 May 2022 | 342,465 | 342,465 (1%) | 1% | 1.5 | 499,999 | Common Stock |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,053 | 64,084 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,873 | 5,747 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,053 | 4,105 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,873 | 66,957 (0%) | 0% | 0 | Common Stock | |
| Jose-Carlos Gutierrez-Ramos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Tonya Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,052 | 59,157 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,874 | 8,620 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,052 | 6,158 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,874 | 62,031 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,873 | 57,105 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,873 | 11,494 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,053 | 8,210 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,053 | 54,232 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,873 | 52,179 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,052 | 49,306 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,873 | 14,367 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,052 | 10,263 | - | - | Restricted Stock Units | |
| Mark D. Plinio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 4.00 per share. | 31 Jan 2022 | 1,250 | 1,250 (0%) | 0% | 4.0 | 5,004 | Common Stock |
| Stephen J. Carriere | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 1,417 | 1,417 | - | - | Restricted Stock Units | |
| Stephen J. Carriere | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 6,250 | 6,250 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Luca Scavo | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Char | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan B. Zung | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Mark D. Plinio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,053 | 39,455 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,873 | 20,114 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,053 | 14,367 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,873 | 42,328 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,873 | 37,402 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,873 | 22,987 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,052 | 16,420 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,052 | 34,529 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,053 | 18,472 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,874 | 25,860 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,874 | 32,477 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,053 | 29,603 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 4,104 | 21,804 (0%) | 0% | 0 | Common Stock | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 5,746 | 28,734 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 4,104 | 20,525 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 5,746 | 27,550 (0%) | 0% | 0 | Common Stock | |
| Iain B. McInnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 24,629 | 24,629 | - | - | Restricted Stock Units | |
| David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 34,480 | 34,480 | - | - | Restricted Stock Units | |
| Melas Theo Kyriazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 1,810 | 1,810 | - | - | Stock Option (Right to Buy) | |
| Melas Theo Kyriazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| David Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 1,810 | 1,810 | - | - | Stock Option (Right to Buy) | |
| David Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 1,810 | 1,810 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 1,810 | 1,810 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Luca Scavo | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 4,545 | 4,545 | - | - | Restricted Stock Units | |
| Luca Scavo | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Julie H. McHugh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2021 | 31,380 | 31,380 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| John A. Hohneker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 31,380 | 31,380 | - | - | Stock Option (Right to Buy) | |
| Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 96,500 | 96,500 | - | - | Stock Option (Right to Buy) | |
| Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 179,000 | 179,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Char | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 57,000 | 57,000 | - | - | Stock Option (Right to Buy) | |
| Xiaoli Liu | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Xiaoli Liu | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 5,680 | 5,680 | - | - | Restricted Stock Units | |
| Jonathan B. Zung | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Jonathan B. Zung | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.40 per share. | 11 Dec 2020 | 200 | 10,200 (0%) | 0% | 6.4 | 1,280 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 7.02 per share. | 11 Dec 2020 | 200 | 17,700 (0%) | 0% | 7.0 | 1,404 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.98 per share. | 11 Dec 2020 | 500 | 17,500 (0%) | 0% | 7.0 | 3,490 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.91 per share. | 11 Dec 2020 | 1,000 | 17,000 (0%) | 0% | 6.9 | 6,910 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 7.16 per share. | 11 Dec 2020 | 800 | 16,000 (0%) | 0% | 7.2 | 5,728 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.49 per share. | 11 Dec 2020 | 4,970 | 15,200 (0%) | 0% | 6.5 | 32,255 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.47 per share. | 11 Dec 2020 | 30 | 10,230 (0%) | 0% | 6.5 | 194 | Common Stock |
| Xiaoli Jacqueline Liu | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 5.17 per share. | 01 Dec 2020 | 3,000 | 0 (0%) | 0% | 5.2 | 15,510 | Common Stock |
| David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2020 | 44,743 | 44,743 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2020 | 59,395 | 59,395 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.34 per share. | 28 Aug 2020 | 1,000 | 1,000 (0%) | 0% | 4.3 | 4,340 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.40 per share. | 28 Aug 2020 | 3,248 | 4,248 (0%) | 0% | 4.4 | 14,291 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.46 per share. | 28 Aug 2020 | 2,752 | 7,000 (0%) | 0% | 4.5 | 12,274 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.47 per share. | 28 Aug 2020 | 1,000 | 8,000 (0%) | 0% | 4.5 | 4,470 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.48 per share. | 28 Aug 2020 | 1,000 | 9,000 (0%) | 0% | 4.5 | 4,480 | Common Stock |
| David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 28 Aug 2020 | 1,000 | 10,000 (0%) | 0% | 4.6 | 4,580 | Common Stock |
| Xiaoli Jacqueline Liu | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Melas Theo Kyriazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| David Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Neil Graham | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2020 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Poole | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Poole | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 106,000 | 106,000 | - | - | Stock Option (Right to Buy) | |
| Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Char | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2020 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Juan Andres | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2019 | 31,380 | 31,380 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2019 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2019 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| David R. Epstein | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Melas Theo Kyriazi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Nancy A. Simonian | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Noubar B. Afeyan | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| David Perry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Ara Darzi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2019 | 15,690 | 15,690 | - | - | Stock Option (Right to Buy) | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2019 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Poole | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bodmer | CSO, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Char | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2018 | 100,000 | 100,000 | - | - | Stock Option | |
| Nancy A. Simonian | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2018 | 31,380 | 31,380 | - | - | Stock Option | |
| Simba Gill | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2018 | 145,869 | 145,869 | - | - | Stock Option | |
| Jonathan Poole | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2018 | 71,497 | 71,497 | - | - | Stock Option | |
| Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2018 | 79,052 | 79,052 | - | - | Stock Option | |
| Mark Bodmer | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2018 | 55,437 | 55,437 | - | - | Stock Option |